Gilead Awarded $175.2 Million Over HIV Drug Fraud Scheme

A federal judge in Florida has awarded Gilead Sciences $175.2 million in damages over charges that the defendants fraudulently enrolled individuals in Gilead’s Medication Assistance Program then resold the company’s free PrEP HIV drugs Truvada (emtricitabine and tenofovir disoproxil fumarate) and Descovy (emtricitabine and tenofovir alafenamide).

The company filed its complaint in November 2020, seeking an injunction to halt the alleged “dangerous and fraudulent” schemes.

The judgment permanently blocks defendants Baikal Marketing Group, the Priority Health Medical Center and several individuals from enrolling or facilitating the enrollment of any individual in Gilead’s Patient Assistance Program, Medication Assistance Program or any program that provides access to free Gilead medication.